Larger HIV Reservoirs Track With Aging Biology and Chronic Disease Burden on ART
In people with HIV receiving suppressive antiretroviral therapy, the viral reservoir is no longer a purely virologic concept. This preprint links reservoir size and transcriptional activity to biological aging scores and to several non-AIDS comorbidities, suggesting that persistent HIV persistence may mirror broader systemic risk even when plasma virus is controlled.
The analysis drew on 1,895 people with HIV in the 2000HIV cohort and focused on circulating CD4+ T cells, where proviral DNA and cell-associated HIV RNA can be measured even under treatment. Investigators assessed both total and intact proviral HIV DNA, along with transcriptional activity, then related those markers to historical and prospective virologic and immunologic response measures, comorbidity outcomes, and aging-related scores. The central clinical question is straightforward: does a larger reservoir merely mark earlier uncontrolled infection, or does it identify people whose long-term health trajectory remains biologically altered despite antiretroviral suppression?
The answer here leans toward the second interpretation.
Reservoir Markers Were Tied to Residual Viremia and Older Aging Scores
Reservoir markers were highly correlated with one another, which is clinically relevant because it suggests a coherent biological signal rather than a single assay behaving idiosyncratically. Larger reservoir burden tracked with older biological aging scores and with adverse virologic findings, including quantifiable and residual viremia at study entry and during follow-up. In other words, people with more persistent HIV material in circulating CD4+ T cells also tended to show a less favorable virologic footprint over time, even while remaining on therapy.
This pattern fits with the biology of latent and transcriptionally active infection. HIV DNA locked into long-lived immune cells can remain a stable archive of prior replication, while ongoing low-level transcription may reflect persistent cellular activity that suppressive therapy does not fully extinguish. Even when plasma HIV is clinically suppressed, a larger cellular reservoir may still signal ongoing immune perturbation, clonal expansion of infected cells, or longer exposure to host pathways that contribute to tissue injury and physiologic aging.
Total HIV DNA Carried the Strongest Links to Comorbidity
The clearest associations came from total HIV DNA, not from the smaller intact DNA fraction. Total HIV DNA correlated with prevalent cardiovascular disease, subclinical atherosclerotic disease, liver fibrosis, and incident malignancies. These relationships persisted independently of circulating inflammatory markers and the lowest historical CD4 nadir, which makes the signal harder to dismiss as a simple reflection of generalized immune suppression or measured inflammation alone.
That distinction matters at the bedside. A marker that continues to associate with cardiovascular, hepatic, and oncologic outcomes after adjustment for inflammatory markers suggests the reservoir may sit upstream of pathways not fully captured by routine clinical labs. Chronic HIV persistence can plausibly interact with endothelial dysfunction, monocyte activation, fibrotic remodeling, and altered immune surveillance. Those mechanisms are biologically compatible with premature atherosclerosis, hepatic injury, and malignancy risk in treated HIV, even when standard viral suppression is maintained.
A second finding stood out: total HIV RNA also associated with prevalent cardiovascular disease and liver fibrosis. Transcriptionally active reservoir burden may therefore be especially relevant in patients whose infection is not entirely silent at the cellular level. Persistent RNA production can imply active host-cell engagement, and that state may be more tightly linked to organ injury than the mere presence of defective proviral fragments.
Intact Provirus Did Not Mirror the Same Clinical Signal
One of the more interesting asymmetries in the dataset is that the minor fraction of intact HIV DNA did not show the same breadth of association as total HIV DNA. That may reflect the different biological meanings of these assays. Intact proviruses represent replication-competent virus, but they are rare, while total HIV DNA includes a much broader collection of defective and intact sequences that may better capture cumulative infection burden, infected-cell turnover, and the host environment in which the reservoir is maintained.
From a clinical perspective, this means the reservoir should not be viewed as a single entity with one readout. The compartment measured by total proviral DNA may be more informative for comorbidity risk than the narrower intact fraction, at least in this cohort. The data also point toward a broader principle in HIV medicine: long-term risk may be shaped not only by what remains replication competent, but by the total cellular imprint of persistent infection.
What Reservoir Reduction Could Mean for Future HIV Care
The practical implication is not that reservoir testing is ready for routine management today. It is that people with high reservoir markers may represent a subgroup in which chronic disease prevention deserves closer attention, and possibly a different therapeutic strategy in future studies. If reservoir burden helps identify those at greatest risk for cardiovascular disease, liver fibrosis, malignancy, and accelerated aging, then reservoir-directed interventions could eventually become relevant beyond cure research alone.
For now, the preprint raises a disciplined and important hypothesis: reducing the HIV reservoir may do more than advance eradication science; it may also alter the risk profile for non-AIDS illness in treated patients. Whether that proves true will depend on intervention studies that can show not just reservoir shrinkage, but measurable change in clinical outcomes. The current report does not answer that question, and it should not be read as proof that lowering reservoir markers will lower event rates.
What it does provide is a strong biologic and epidemiologic signal across a large treated cohort: persistent HIV burden, aging biology, and chronic disease appear to travel together, even under suppressive antiretroviral therapy.